Affiliation:
1. Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242,1 and
2. Disciplina de Doenças Infecciosas e Parasitàrias, Universidade Federal de São Paulo, São Paulo, Brazil2
Abstract
ABSTRACT
The emergence of infections caused by multidrug-resistant
Pseudomonas aeruginosa
and
Acinetobacter
spp. has necessitated the search for alternative parenteral agents such as the polymyxins. The National Committee for Clinical Laboratory Standards (NCCLS) documents do not currently provide interpretative criteria for the testing of the polymyxins, colistin and polymyxin B. Therefore, an evaluation of the antimicrobial activity of colistin and polymyxin B was initiated using 200 bloodstream infection pathogens collected through the SENTRY Antimicrobial Surveillance Program. All susceptibility tests were performed according to the NCCLS recommendations. Polymyxin B and colistin displayed a nearly identical spectrum of activity, exhibiting excellent potency against
P. aeruginosa
(MIC
90
, 2 μg/ml) and
Acinetobacter
sp. (MIC
90
, 2 μg/ml). In contrast, they showed limited activity against some other nonfermentative bacilli such as
Burkholderia cepacia
(MIC
90
, ≥128 μg/ml). Excellent correlation was achieved between broth microdilution and agar dilution tests (
r
= 0.96 to 0.98); 94.3% of the results were ±1 log
2
dilution between the methods used for both compounds. At a resistance breakpoint of ≥4 μg/ml for both agents, unacceptable false-susceptible or very major errors were noted for colistin (5%) and polymyxin B (6%). Modified zone criteria for colistin (≤11 and ≥14 mm) and polymyxin B (≤10 and ≥14 mm) were suggested, but some degree of error persisted (≥3.5%). It is recommended that all susceptible disk diffusion results be confirmed by MIC tests using the preferred reference NCCLS method. The quality control (QC) ranges listed in the product package insert require an adjusted range by approximately 3 mm for both NCCLS gram-negative quality control strains. This evaluation of in vitro susceptibility test methods for the polymyxin class drugs confirmed continued serious testing error with the disk diffusion method, the possible need for breakpoint adjustments, and the recalculation of disk diffusion QC ranges. Clinical laboratories should exclusively use MIC methods to assist the therapeutic application of colistin or polymyxin B until disk diffusion test modifications are sanctioned and published by the NCCLS.
Publisher
American Society for Microbiology
Cited by
288 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献